Genetic testing for neurotrophic receptor tyrosine kinase (NTRK) fusion in patients with locally advanced or metastatic solid tumours

This page contains information about the 1 July 2022 listing of four new MBS items for NTRK fusion.

Page last updated: 27 June 2022

From 1 July 2022, patients less than 18 years of age with locally advanced or metastatic solid tumours of any origin and adult patients with locally advanced or metastatic mammary analogue secretory carcinoma of the salivary gland or locally advanced or metastatic secretory breast carcinoma will be able to access Medicare Benefits Schedule (MBS) funded genetic testing for NTRK gene fusion status, to determine eligibility for access to a tropomyosin receptor kinase (Trk) inhibitor under the Pharmaceutical Benefits Schedule (PBS).

PDF Version - 1 July 2022 listing of four new MBS items for NTRK fusion testing (PDF 124 KB)

Word Version - 1 July 2022 listing of four new MBS items for NTRK fusion testing (Word 91 KB)

In this section